Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862–73.

Article  CAS  PubMed  Google Scholar 

Lu Y, Zhang H, Lu J, Ding Q, Li X, Wang X, et al. Prevalence of dyslipidemia and availability of lipid-lowering medications among primary health care settings in China. JAMA Netw Open. 2021;4: e2127573.

Article  PubMed  PubMed Central  Google Scholar 

Zheng W, Zhang YJ, Bu XT, Guo XZ, Hu DY, Li ZQ, et al. LDL-cholesterol goal attainment under persistent lipid-lowering therapy in northeast China: subgroup analysis of the dyslipidemia international study of China (DYSIS-China). Medicine (Baltimore). 2017;96: e8555.

Article  PubMed  Google Scholar 

Li S, Liu HH, Guo YL, Zhu CG, Wu NQ, Xu RX, et al. Improvement of evaluation in Chinese patients with atherosclerotic cardiovascular disease using the very-high-risk refinement: a population-based study. Lancet Reg Health West Pac. 2021;17: 100286.

Article  PubMed  PubMed Central  Google Scholar 

Bi L, Yi J, Wu C, Hu S, Zhang X, Lu J, et al. Atherosclerotic cardiovascular disease risk and lipid-lowering therapy requirement in China. Front Cardiovasc Med. 2022;9: 839571.

Article  PubMed  PubMed Central  Google Scholar 

Gao F, Zhou YJ, Hu DY, Zhao YX, Liu YY, Wang ZJ, et al. Contemporary management and attainment of cholesterol targets for patients with dyslipidemia in China. PLoS ONE. 2013;8: e47681.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart disease and stroke statistics—2022 update: a report from the American Heart Association. Circulation. 2022;145:e153–639.

Article  PubMed  Google Scholar 

Chinese guidelines for lipid management (2023). Zhonghua xin xue guan bing za zhi. 2023;51.

Egom EE, Hafeez H. Biochemistry of statins. Adv Clin Chem. 2016;73:127–68.

Article  CAS  PubMed  Google Scholar 

Sizar O, Khare S, Jamil RT, Talati R. Statin medications. Treasure Island: StatPearls; 2022.

Google Scholar 

Bansal AB, Cassagnol M. HMG-CoA reductase inhibitors. Treasure Island: StatPearls; 2022.

Google Scholar 

Mitchell JD, Fergestrom N, Gage BF, Paisley R, Moon P, Novak E, et al. Impact of statins on cardiovascular outcomes following coronary artery calcium scoring. J Am Coll Cardiol. 2018;72:3233–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang X, Xing L, Jia X, Pang X, Xiang Q, Zhao X, et al. Comparative lipid-lowering/increasing efficacy of 7 statins in patients with dyslipidemia, cardiovascular diseases, or diabetes mellitus: systematic review and network meta-analyses of 50 randomized controlled trials. Cardiovasc Ther. 2020;2020:3987065.

Article  PubMed  PubMed Central  Google Scholar 

Hodkinson A, Tsimpida D, Kontopantelis E, Rutter MK, Mamas MA, Panagioti M. Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis. BMJ. 2022;376: e067731.

Article  PubMed  PubMed Central  Google Scholar 

Zhang L, Zhang S, Yu Y, Jiang H, Ge J. Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol: a meta-analysis of trials with East Asian populations. Herz. 2020;45:594–602.

Article  CAS  PubMed  Google Scholar 

Šimić I, Reiner Ž. Adverse effects of statins—myths and reality. Curr Pharm Des. 2015;21:1220–6.

Article  PubMed  Google Scholar 

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279–91.

Tomlinson B, Chan P, Liu ZM. Statin intolerance—an Asian perspective. J Atheroscler Thromb. 2020;27:485–8.

Article  PubMed  PubMed Central  Google Scholar 

Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005;78:330–41.

Article  CAS  PubMed  Google Scholar 

Bitzur R, Cohen H, Kamari Y, Harats D. Intolerance to statins: mechanisms and management. Diabetes Care. 2013;36(Suppl 2):S325–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

2016 Chinese guidelines for the management of dyslipidemia in adults. J Geriatr Cardiol. 2018;15:1–29.

Sizar O, Nassereddin A, Talati R. Ezetimibe. Treasure Island: StatPearls; 2022.

Google Scholar 

Zhan S, Tang M, Liu F, Xia P, Shu M, Wu X. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database Syst Rev. 2018;11:C012502.

Google Scholar 

Vavlukis M, Vavlukis A. Adding ezetimibe to statin therapy: latest evidence and clinical implications. Drugs Context. 2018;7: 212534.

Article  PubMed  PubMed Central  Google Scholar 

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88.

Article  PubMed  Google Scholar 

Ma YB, Chan P, Zhang Y, Tomlinson B, Liu Z. Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia. Expert Opin Pharmacother. 2019;20:917–28.

Article  CAS  PubMed  Google Scholar 

Hennekens CH. Fixed-dose combination therapy with statins: strengths, limitations, and clinical and regulatory considerations. Am J Cardiovasc Drugs. 2008;8:155–60.

Article  CAS  PubMed  Google Scholar 

Hong SJ, Jeong HS, Ahn JC, Cha DH, Won KH, Kim W, et al. A Phase III, multicenter, randomized, double-blind, active comparator clinical trial to compare the efficacy and safety of combination therapy with ezetimibe and rosuvastatin versus rosuvastatin monotherapy in patients with hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) randomized controlled trial. Clin Ther. 2018;40:226-41.e4.

Article  CAS  PubMed  Google Scholar 

Lee SA, Kim W, Hong TJ, Ahn Y, Kim MH, Hong SJ, et al. Effects of fixed-dose combination of low-intensity rosuvastatin and ezetimibe versus moderate-intensity rosuvastatin monotherapy on lipid profiles in patients with hypercholesterolemia: a randomized, double-blind, multicentre, Phase III study. Clin Ther. 2021;43:1573–89.

Article  CAS  PubMed  Google Scholar 

Farnier M, Averna M, Missault L, Vaverkova H, Viigimaa M, Massaad R, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy—the IN-CROSS study. Int J Clin Pract. 2009;63:547–59.

Article  CAS  PubMed  Google Scholar 

Catapano AL, Vrablik M, Karpov Y, Berthou B, Loy M, Baccara-Dinet M. A Phase 3 randomized controlled trial to evaluate efficacy and safety of new-formulation zenon (rosuvastatin/ezetimibe fixed-dose combination) in primary hypercholesterolemia inadequately controlled by statins. J Cardiovasc Pharmacol Ther. 2022;27:10742484221138284.

Article  CAS  PubMed  Google Scholar 

Kim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, Hong BK, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022;400:380–90.

Article  CAS  PubMed  Google Scholar 

Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007;99:673–80.

Article  CAS  PubMed  Google Scholar 

Kim KJ, Kim SH, Yoon YW, Rha SW, Hong SJ, Kwak CH, et al. Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe). Cardiovasc Ther. 2016;34:371–82.

Article  CAS  PubMed  Google Scholar 

Yang YJ, Lee SH, Kim BS, Cho YK, Cho HJ, Cho KI, et al. Combination therapy of rosuvastatin and ezetimibe in patients with high cardiovascular risk. Clin Ther. 2017;39:107–17.

Article  CAS  PubMed  Google Scholar 

Xia B, Lin P, Ji Y, Yin J, Wang J, Yang X, et al. Ezetimibe promotes CYP7A1 and modulates PPARs as a compensatory mechanism in LDL receptor-deficient hamsters. Lipids Health Dis. 2020;19:24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Polis AB, Abate N, Catapano AL, Ballantyne CM, Davidson MH, Smugar SS, et al. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. Metab Syndr Relat Disord. 2009;7:601–10.

Article  CAS  PubMed  Google Scholar 

Kamat SA, Bullano MF, Chang CL, Gandhi SK, Cziraky MJ. Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population. Curr Med Res Opin. 2011;27:961–8.

Article  CAS  PubMed  Google Scholar 

Rea F, Savaré L, Corrao G, Mancia G. Adherence to lipid-lowering treatment by single-pill combination of statin and ezetimibe. Adv Ther. 2021;38:5270–85.

Article  CAS